Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

829.74 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction. 
Via Benzinga
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? 
Via InvestorPlace
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Healthcare stocks disappointed again last week with the XLV down over 3% and up only 1.65 % YTD, in a continued downtrend since March 28. 
Via Talk Markets
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money. 
Via InvestorPlace
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund? 
Via The Motley Fool
Novo Nordisk Arms Wegovy to Be a Triple Threat
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders 
Via MarketBeat
3 Magnificent Stocks That Could Double or More by 2030
There's no guarantee these stocks will double by 2030, but their growth prospects look great. 
Via The Motley Fool
This Vanguard ETF Has Skyrocketed 40% in 12 Months. Is It a No-Brainer Buy Right Now?
You can own a basket of tremendously successful stocks with this ETF. 
Via The Motley Fool
Topics ETFs
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
A powerfully bullish new analyst take on the company helped it rally on the market. 
Via The Motley Fool
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled... 
Via Benzinga
Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy
U.S. District Judge Roy Altman's ruling prohibits Eli Lilly from using state law to halt RXCompoundStore.com's marketing of its tirzepatide version. The court asserts federal law enforcement authority,... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough... 
Via Benzinga
Exposures Product Safety
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
Continuous glucose monitors have spiked in popularity since the advent of weight-loss drugs. Is chronic disease at its end? 
Via Investor's Business Daily
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades. 
Via InvestorPlace
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
For investors looking for a way to play weight-loss stocks in this current backdrop, here are three top options to consider right now. 
Via InvestorPlace
Why Roche Holdings Stock Popped Today
Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate. 
Via The Motley Fool
Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for April 2024
Investors wanting to broaden and deepen their portfolio should reach for these healthcare names, each of which is a favorite among analysts. 
Via InvestorPlace
Trillion-Dollar Trajectories: 3 Billion-Dollar Stocks With the Potential to Hit the Next Milestone
Looking for your next picks? These top-performing market leaders have the potential to be the next trillion-dollar companies. 
Via InvestorPlace
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments 
Via InvestorPlace
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections... 
Via Benzinga
The Next "Magnificent Seven"?
Here is a look at the stocks that might comprise the next "Magnificent Seven." 
Via The Motley Fool
Jim Cramer Stands By Nvidia And Eli Lilly Despite Market Dips, Says 'Terrific Time To Take Some Profits'
Cramer observed that despite the losses, these stocks have a lot to offer. He noted that these stocks have surged so much that they've become susceptible to market volatility. 
Via Benzinga
MarketMasterAI’s Top 500 Stocks: April 2024
My MarketMasterAI system has ranked the top 500 stocks to buy in April and the winners look really different than in January. Here's why. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term. 
Via InvestorPlace
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
These companies are close to launching new products that could supercharge revenue. 
Via The Motley Fool
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market 
Via MarketBeat
Exposures Product Safety
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These stocks, a bargain today, are players to hold on to for the long term. 
Via The Motley Fool
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.